NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection ...

Wave's pivotal trial, Dr. William Abraham is working on another heart failure trial as the new CMO at Cardiac Dimensions.

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...

A once-daily polypill containing 3 guideline-directed therapies for heart failure with reduced ejection fraction (HFrEF) led ...

A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In a recent study, his group and ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

Dr Yaranov highlights that heart failure can start quietly. He shares 7 early signs, and stresses the importance of ...

Prioritizing education and shared decision-making can help patients with newly diagnosed heart failure feel less overwhelmed, ...

Background: Cardiovascular disease (CVD) causes more than 50% of deaths in patients with advanced chronic kidney disease (CKD). Clinical studies suggest that kidney-derived factors contribute to CVD ...